In c-KIT-mutant melanoma, several RTK inhibitors have been tested in the clinical space, with comparable overall response rates (ORR) reported for imatinib (23.3%) and nilotinib (26.2%), and slightly lower rates for dasatinib (18.2%) [30,31,32]. Here, KIT is linked to melanoma.